- Home
- CRGX vs CSR Comparison
CRGX vs CSR Comparison
Compare CRGX & CSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- CSR
- Stock Information
- Founded
- CRGX 2021
- CSR 1970
- Country
- CRGX United States
- CSR United States
- Employees
- CRGX N/A
- CSR N/A
- Industry
- CRGX
- CSR Real Estate Investment Trusts
- Sector
- CRGX
- CSR Real Estate
- Exchange
- CRGX Nasdaq
- CSR Nasdaq
- Market Cap
- CRGX 964.5M
- CSR 1.1B
- IPO Year
- CRGX 2023
- CSR N/A
- Fundamental
- Price
- CRGX $12.81
- CSR $65.87
- Analyst Decision
- CRGX Strong Buy
- CSR Buy
- Analyst Count
- CRGX 6
- CSR 7
- Target Price
- CRGX $31.80
- CSR $71.50
- AVG Volume (30 Days)
- CRGX 229.0K
- CSR 95.8K
- Earning Date
- CRGX 11-12-2024
- CSR 10-28-2024
- Dividend Yield
- CRGX N/A
- CSR 4.55%
- EPS Growth
- CRGX N/A
- CSR N/A
- EPS
- CRGX N/A
- CSR N/A
- Revenue
- CRGX N/A
- CSR $258,642,000.00
- Revenue This Year
- CRGX N/A
- CSR N/A
- Revenue Next Year
- CRGX N/A
- CSR $3.55
- P/E Ratio
- CRGX N/A
- CSR N/A
- Revenue Growth
- CRGX N/A
- CSR N/A
- 52 Week Low
- CRGX $12.58
- CSR $20.10
- 52 Week High
- CRGX $33.92
- CSR $76.16
- Technical
- Relative Strength Index (RSI)
- CRGX 30.99
- CSR 24.99
- Support Level
- CRGX $13.33
- CSR $68.88
- Resistance Level
- CRGX $15.26
- CSR $70.32
- Average True Range (ATR)
- CRGX 1.36
- CSR 1.46
- MACD
- CRGX -0.30
- CSR -0.50
- Stochastic Oscillator
- CRGX 3.51
- CSR 3.06
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and they conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.